BriaCell CEO: Incyte Collaboration Enabling New Clinical Trials for Breast Cancer Treatments

BriaCell Therapeutics CEO Dr. Bill Williams joined the Investing News Network to discuss his company’s progress in developing an innovative immunotherapy to treat breast cancer.

With 12 percent of women in the US expected to develop a form of breast cancer at some point in their life, there is an urgent need for solutions to combat one of the most common forms of cancer in the world today.

In pursuit of this goal, biotechnology company BriaCell Therapeutics (TSX:BCT,OTCQB:BCTXF) has developed an innovative immunotherapy designed to treat breast cancer by leveraging the body’s natural immune responses. The treatment, Bria-IMT, has reached positive proof of concept with encouraging safety and efficacy data.

BriaCell has recently entered into a collaboration with Incyte (NASDAQ:INCY) to evaluate the potential efficacy of combining BriaCell’s Bria-IMT with Incyte’s innovative drug compounds. According to BriaCell CEO Dr. Bill Williams, the goal of the collaboration is to reach the end of phase two so that the company can begin discussions with the FDA in order to negotiate the design of a potential research study.

Below is a transcript of our interview with BriaCell CEO Dr. Bill Williams. It has been edited for clarity and brevity.

Investing News Network: BriaCell has had some interesting developments lately. Can you tell us more about last week’s news?

BriaCell CEO Dr. Bill Williams: Before we get started, it’s important to note the following statistics about breast cancer. According to the latest report by the American Cancer Society, the average risk of a woman developing breast cancer sometime in her life is about 12 percent. This means there is a one in eight chance she will develop breast cancer. Breast cancer deaths in 2019 are estimated at 42,260, which is 15 each day, making breast cancer the second leading cause of cancer death in women after lung cancer. These are the women BriaCell is treating, women with no other options. It is very sad to note that no effective treatment option for this patient population currently exists, making advanced breast cancer an urgent and unmet medical need.

We recently reported on a robust responder, a woman who experienced a highly remarkable reduction in breast cancer tumors in the adrenal gland and the outer lining of the brain, had developed tumors that had metastasized to areas outside of her breasts. Prior to our treatment, which entailed a combination of BriaCell’s Bria-IMT and KEYTRUDA, she had failed 12 prior regimens with 16 agents, 13 chemotherapy and three hormonal. The patient remains on treatment.

INN: Could you elaborate on the significance of today’s commencement of your collaboration with Incyte?

BW: BriaCell has a non-exclusive clinical trial collaboration with Incyte to evaluate the effects of combinations of BriaCell’s novel clinical candidates with Incyte’s drugs in cancer patients. Incyte is a global biopharmaceutical company focused on discovering and developing novel therapeutics in oncology and other serious diseases. They have a deep and rich pipeline in immuno-oncology with numerous molecular targets. Under our collaboration, Incyte is providing compounds from its development portfolio, including INCMGA0012, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with BriaCell’s product candidates.

As a former executive of Incyte Corporation, I have been following the progress of Incyte’s clinical candidates including Incyte’s INCMGA00012, which blocks PD-1, similar to KEYTRUDA, and Incyte’s epacadostat, an investigational drug for cancer. We realized that these agents could potentially boost the activity of Bria-IMT in advanced breast cancer patients.

I am very pleased to announce that we have initiated dosing in a Phase I/IIa clinical study of Bria-IMT in combination with Incyte’s INCMGA00012 in patients with advanced breast cancer that has progressed following standard of care therapies.

The study design includes an initial group of patients to be treated with the Bria-IMT regimen in combination with INCMGA00012 to establish safety. A subsequent group of patients will be treated with the triple combination of the Bria-IMT with INCMGA00012 and epacadostat. The dose of epacadostat has been established to be safe when given in combination with INCMGA00012 in patients with cancer. The goal is to remove cancer-induced suppression of the immune system, thereby awakening the immune system to destroy cancer cells. This should permit the potent immune responses induced by the Bria-IMT regimen to selectively and forcefully attack the cancer cells.

INN: How will the results of the clinical study impact BriaCell moving forward?

BW: The results of this clinical study will be particularly significant because they will allow us to meet with the FDA to design and determine the amount of the additional clinical data required for marketing approval of the combination of Bria-IMT with Incyte’s compounds as treatment for advanced breast cancer patients. The resulting data will help BriaCell in its ongoing discussions with big pharma players to potentially secure lucrative partnership deals. Most importantly, these studies will advance Bria-IMT’s combination treatments towards marketing authorization, so the novel treatments can become available to patients with advanced breast cancer who are suffering from this terrible disease and have few to no treatment options.

INN: What’s next for the Incyte collaboration, and how does that fit into BriaCell’s long-term goals?

BW: Near-term, we’re focused on our Phase I/IIa clinical study of Bria-IMT in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. The goal is to advance this program to an “end of phase II” meeting with the FDA where we will negotiate the design of our registration study. This will be a major driver for the company, as once the design of the registration study is agreed on, that sets the pathway for marketing approval of the combination for advanced breast cancer patients. This is the point where we’ve seen multi-billion-dollar buyouts and licensing deals with big pharma players. We continue to have discussions with these big pharma companies that have active merger and acquisition mandates for immunotherapy approaches, like BriaCell’s Bria-IMT.


This interview is sponsored by BriaCell Therapeutics (TSXV:BCT,OTCQB:BCTXF). This interview provides information which was sourced by the Investing News Network (INN) and approved by BriaCell Therapeutics in order to help investors learn more about the company. BriaCell Therapeutics is a client of INN. The company’s campaign fees pay for INN to create and update this interview.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with BriaCell Therapeutics and seek advice from a qualified investment advisor.

This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.

Featured
Western Copper and Gold CEO: We’re Western Copper and Gold for a Good Reason

“We’ve got 21 million ounces of gold and 11 billion pounds of copper in our overall resource at Casino. Very significant from both a copper and gold perspective. So we’re Western Copper and Gold for a good reason,” shared Western Copper and Gold CEO Paul West-Sells.

Western Copper and Gold (TSX:WRN,NYSE:WRN) is currently sitting on a resource that’s composed of 21 million ounces of gold and 11 billion pounds of copper.

Western Copper and Gold CEO Paul West-Sells views this as a significant endowment for the company and its shareholders, as well as for Canada and the Yukon.

“We’ve got 21 million ounces of gold and 11 billion pounds of copper in our overall resource at Casino. Very significant from both a copper and gold perspective. So we’re Western Copper and Gold for a good reason. And that’s where the value is in the ground,” said West-Sells.

In June 2021, the company announced a positive preliminary economic assessment at its wholly owned Casino copper-gold-molybdenum deposit in the Yukon. Western Copper and Gold will conduct a feasibility study on Casino, and it is targeted to be completed by the second quarter of 2022.

“The other big push for us is to get the permitting going. We now have money in the bank, and we just hired a vice president of permitting to move the project. More importantly, we now have Rio Tinto (ASX:RIO,LSE:RIO,NYSE:RIO) as a strategic investor, which was the last piece that was really missing. This is a big project. A lot of ounces, a lot of pounds, a lot of upfront capital to get those out of the ground.”

Western Copper and Gold completed a brokered private placement for aggregate gross proceeds of $8,010,000 that will be used to fund “Canadian exploration expenses” and “flow-through mining expenditures.”

Watch the full interview of Western Copper and Gold CEO Paul West-Sells above.

read more Show less
Novo Resources Executive Co-Chairman Michael Spreadborough: Well Financed to Bring Exploration Projects into Production

Novo Resources Executive Co-Chairman Michael Spreadborough said the company has a strong balance sheet to keep advancing its projects toward production.

Novo Resources (TSXV:NVO) recently announced it has intersected high-grade gold at its Talga Talga gold project and has accelerated the near-mine exploration program at its Nullagine gold project in Western Australia. Novo Resources Executive Co-Chairman Michael Spreadborough said the company has a strong balance sheet to keep advancing its projects towards production.

“We are sitting at approximately $50 million cash at the moment, (and) have a strategic investment portfolio that’s worth roughly C$150 million. Our balance sheet is very, very strong with enough horsepower to do the exploration work. We are in a very strong position to keep us moving forward,” he shared.

Novo Resources’ exploration program has been accelerated with additional funding of up to AU$2.5 million to support near-mine exploration. The amount is on top of the previously approved AU$12 million. Novo Resources is aiming to accelerate the delineation of targets in the Mosquito Creek Basin that have the potential to provide additional oxide mill feed to the Golden Eagle processing facility

“We like to play with innovation, we like to be leaders in some of the things that we’re doing. So we’re very focused on ore sorting. Innovation is a big focus in our culture. We’re putting over $15 million a year into exploration as we develop more targets to bring into production,” said Spreadborough.

“We’ve already found good gold discoveries, we’ll probably find more as we do more work. We’ve got the horsepower financially and we’ve got that ability. We’ve demonstrated now that we can take exploration projects all the way through to development and into production. We have the complete skill set. We think we’re in a good position right now to move the company forward,” he added.

Watch the full interview of Novo Resources Executive Co Chair Michael Spreadborough above.

read more Show less
Azincourt Energy CEO Alex Klenman: Applying Artificial Intelligence to Uranium Exploration in the Athabasca Basin

“Nobody’s really applying artificial intelligence into the uranium exploration in the Athabasca, and so we might be a first mover,” said Azincourt Energy CEO Alex Klenman.

Azincourt Energy (TSXV:AAZ,OTCQB:AZURF,FWB:A0U2) CEO Alex Klenman discussed the company’s pioneering initiatives to bring artificial intelligence (AI), data mining and rapid algorithm work into mining exploration.

Azincourt Energy recently entered into an agreement with FOBI AI (TSXV:FOBI) to apply its established AI and applications “to support Azincourt’s goal of making discovery and delineating a resource at its East Preston uranium project,” according to a press release.

“Nobody’s really applying AI into the uranium exploration in the Athabasca, and so we might be a first mover. We’d like to embrace new technology and see how it can make us more efficient,” said Azincourt Energy CEO Alex Klenman.

According to Klenman, the ultimate goal is to utilize technology to allow Azincourt Energy to make discoveries more quickly, with less impact on the environment and with fewer dollars spent on drill holes and exploration initiatives.

The company recently closed the final tranche of a private placement worth $8 million, which will be used to fund the development of the East Preston uranium project. The flagship East Preston project covers over 25,000 hectares in the Western Athabasca Basin, Saskatchewan.

“We’re heading into our drill program in the winter, and we’re going to do 30 to 35 holes. We’re exceeding the entire pre-run here for four years. We have strong institutional support from funds, which allows us to get more aggressive. Our timing looks really good. We’re excited to be cashed up and doing our biggest drill program and the best market we’ve seen since 2011,” shared Azincourt Energy CEO Alex Klenman.

Watch the full interview of Azincourt Energy CEO Alex Klenman above.

read more Show less
text saying "top stories this week"

Catch up and get informed with this week's content highlights from Charlotte McLeod, our editorial director.

Top Stories This Week: Powell Gets Fed Nomination, Using Gold in a Market Correction youtu.be

We're back after a break last week with quite a bit to cover in the gold space.

After running up past the US$1,860 per ounce mark midway through November, the yellow metal has taken a tumble. At the time of this writing on Friday (November 26) afternoon, it was sitting just under US$1,790.

Gold's losses this week have been attributed to elements like a stronger US dollar and better Treasury yields, although Jerome Powell's US Federal Reserve chair renomination has pulled other factors into play — some market watchers believe he may move to taper and raise interest rates faster than anticipated.


If the Fed follows its previously laid out timeline for tapering, it will wrap up in mid-2022; the central bank has said it won't raise rates until after that. It has also emphasized that its roadmap may change if necessary.

Looking at the larger picture for gold, I heard recently from Nick Barisheff of BMG Group, who believes the stock market is due for a major correction.

"The market is due for a major correction. What will cause it and when it will happen is anybody's guess — it could be tomorrow, it could be six months from now" — Nick Barisheff, BMG Group

It's impossible to know when this correction will happen, but Nick emphasized the importance of acting before it's too late. He pointed out that investors are typically slow to get out of the market once a crash actually begins — they wait for a turnaround, and by the time it's clear there won't be one, they've experienced big losses.

In his opinion, the solution is to get out of the stock market early and transfer money into gold.

Here's how Nick explained it:

"Instead of taking your money off the table and going into cash … you go to gold (because cash is devaluing daily). Gold will at least hold its own and probably appreciate … so by sitting it out in gold you can wait until the market finishes correcting and then buy back in" — Nick Barisheff, BMG Group

With gold's future in mind, we asked our Twitter followers this week what price they think the metal will be at the end of 2021. By the time the poll closed, most respondents had voted for the US$1,800 to US$1,900 range.

We'll be asking another question on Twitter next week, so make sure to follow us @INN_Resource or follow me @Charlotte_McL to share your thoughts.

Finally, in the cannabis space, INN's Bryan Mc Govern spoke with Dan Ahrens of AdvisorShares to get his thoughts on 2021 trends and what's ahead in 2022.

Dan was candid, and said if he had to choose one word to describe the cannabis market in 2021, it would be "painful." Like many others, he's been disappointed in the industry's performance — while positivity initially ran high due to excitement about potential federal changes in the US, ultimately progress has been slow.

"Cannabis started with a big run-up in January and February ... and things dragged from there" — Dan Ahrens, AdvisorShares

Still, Dan has hope for 2022 and said it will be a "huge year" for cannabis. He believes US reforms will come sooner rather than later, and in his opinion those widely anticipated changes will bring a wave of M&A activity.

Specifically, he expects to see alcohol, tobacco and other consumer packaged goods companies making deals with cannabis players, not just cannabis entities doing transactions with each other.

"Those big alcohol companies, tobacco companies, other consumer packaged goods product companies — they're waiting. They're waiting on the US" — Dan Ahrens, AdvisorShares

Want more YouTube content? Check out our YouTube playlist At Home With INN, which features interviews with experts in the resource space. If there's someone you'd like to see us interview, please send an email to cmcleod@investingnews.com.

And don't forget to follow us @INN_Resource for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

cannabis plant layered with German flag graphic
Dmytro Tyshchenko / Shutterstock

Catch up on some of the biggest news of the week for the cannabis investment world.

Three political parties have formed a coalition in Germany, leading to a new government, and it has promised cannabis reform in the European nation.

Meanwhile, a popular cannabis retailer confirmed consumers will now find its products available for delivery on the Uber Eats mobile application in Ontario.

Keep reading to find out more cannabis highlights from the past five days.


Coalition of parties promises forward-looking cannabis policy

Germany, a country with comprehensive and elaborate medicinal rules for cannabis, is in a time of transition as a new government is set to begin to take over after 16 years of Angela Merkel.

Olaf Scholz, the proposed next chancellor of Germany, leads a three party coalition that will become the country's governing body. As part of its promises, talk of adult-use cannabis regulation has now gained even more momentum. A report from MJBizDaily quotes a German policy document that shows the coalition's stance:

"We are introducing the controlled distribution of cannabis to adults for consumption purposes in licensed shops. This controls the quality, prevents the transfer of contaminated substances and guarantees the protection of minors."

However, despite the promise and excitement, it remains to be seen how these ideas will be applied since no formal regulations have been drafted or approved yet.

Canadian cannabis retailer partners with popular delivery app

Tokyo Smoke, a cannabis retail operator in Canada owned by Canopy Growth (NASDAQ:CGC,TSX:WEED), announced a collaboration agreement with Uber Canada (NYSE:UBER) whereby cannabis consumers will be able to use the Uber Eats app to order products before they visit stores.

While the app won't let consumers get cannabis delivered to them, this new method opens the doors to more dynamic ways of buying cannabis.

"As a market leader in innovation and a platform used by so many Canadians, we believe this is the ideal next offering that can be done safely and conveniently on the Uber Eats app," Mark Hillard, vice president of operations with Tokyo Smoke, said in a press release.

A report from the Canadian Press indicates Ontario is considering allowing dispensaries to have delivery and pickup options made available to consumers permanently. The province allowed some of these purchasing options at the outset of the COVID-19 pandemic, but then removed them.

Lola Kassim, general manager of Uber Eats Canada, said this new end-to-end experience will provide consumers with responsible access to legal cannabis products.

Cannabis company news

  • Organigram Holdings (NASDAQ:OGI,TSX:OGI) issued financial results for its Q4 2021 period. In its report, the company notes a net loss of C$26 million despite a 22 percent uptick in net revenue to C$24.9 million. Beena Goldenberg, the newly appointed CEO of the firm, is encouraged by the market share position earned by the company, which said it became the fourth biggest producer in Canada during the reporting period.
  • Halo Collective (NEO:HALO,OTCQB:HCANF) confirmed the decision for Akanda, its spinoff company focused on international cannabis opportunities, to begin trading on a US exchange. "The number of shares to be offered and the price range for the proposed offering have not yet been determined," the company told investors in a press release.
  • High Tide (NASDAQ:HITI,TSXV:HITI) announced the acquisition of 80 percent of NuLeaf Naturals, a CBD product wellness developer, for an estimated US$31.24 million. The deal includes a three year option clause for High Tide to complete a total acquisition. "As international markets open up and as export regulations evolve, NuLeaf's cGMP-certified facility positions us to take advantage of the global CBD business opportunity," Raj Grover, president and CEO of High Tide, said.
  • Humble & Fume (CSE:HMBL,OTC Pink:HUMBF) released the financial report for its first 2022 fiscal quarter to shareholders and the market. "As the legal cannabis market in North America continues to mature, Humble remains agile and focused on providing a leading solution for brands to scale quickly and retailers to focus on their customers," Joel Toguri, CEO of Humble, said.

Don't forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

MARKETS

Markets
TSX21125.90-487.28
TSXV944.05-31.53
DOW34899.34-905.04
S&P 5004594.62-106.84
NASD15491.66-353.57
ASX7279.30-128.00

COMMODITIES

Commodities
Gold1792.60+0.99
Silver23.13+0.02
Copper4.29-0.18
Palladium1751.49+10.50
Platinum955.50+2.50
Oil68.17-10.22
Heating Oil2.09-0.29
Natural Gas5.49+0.43

DOWNLOAD FREE REPORTS